Drugs / Dex 21-P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01171807 | Jul 2003 → May 2007 | ulcerative colitis | Quince Therapeutics S.p.A. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dex 21-P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01171807 ↗ |
| Modality | Other / unclassified | “new steroid delivery system” NCT01171807 ↗ |
| Route | Intravenous | “infusions of dexamethasone 21-phosphate encapsulated into autologous erythrocytes” PMID 23714676 ↗ Aug 2013 |